A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.

Inclusion criteria

• Advanced solid tumors;
• The ECOGscore is 0 to 1.
• Expected survival ≥3 months.
• Good organ function before first use of the investigational drug.
• Any toxicity associated with previous antitumor therapy must have returned to ≤ grade 1.
• Voluntarily participate in this clinical trial, understand the research procedures and be able to sign the informed consent in person.

Exclusion criteria

• Subjects who have received certain treatment in the prescribed period prior to their first medication;
• Subjects who have undergone major surgery within 6 weeks before the first medication, or who plan to undergo major surgery within 12 weeks after the first medication;
• Subjects who have participated in any other clinical trials and received treatment within 4 weeks prior to the first medication;
• Subjects with third space fluid accumulation that cannot be controlled by drainage or other methods; Subjects with factors affecting drug administration and absorption;
• Subjects with allergic constitution or a history of severe allergies;
• Subjects with active hepatitis B virus (HBV) infection, active hepatitis C virus (HCV) infection, or a history of immunodeficiency;
• Subjects with a history or evidence of high risk cardiovascular disease;
• Subjects with severe lung disease;
• Pregnant and lactating female subjects; Female subjects of childbearing age or male subjectswith fertile partners who were unwilling to take effective contraceptive measures throughout the entire trial period;
• Subjects with a clear history of neurological or psychiatric disorders;
• Other situations in which the investigator did not consider it appropriate to participate in the study.